Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Chinese Patent Office
AstraZeneca
Teva
McKesson
Fish and Richardson
Chubb
Daiichi Sankyo
Deloitte

Generated: December 10, 2017

DrugPatentWatch Database Preview

Umeclidinium bromide; vilanterol trifenatate - Generic Drug Details

« Back to Dashboard

What are the generic sources for umeclidinium bromide; vilanterol trifenatate and what is the scope of umeclidinium bromide; vilanterol trifenatate freedom to operate?

Umeclidinium bromide; vilanterol trifenatate
is the generic ingredient in one branded drug marketed by Glaxosmithkline and is included in one NDA. There are fourteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Umeclidinium bromide; vilanterol trifenatate has two hundred and ninety-three patent family members in forty-three countries and twenty-eight supplementary protection certificates in twelve countries.

There is one drug master file entry for umeclidinium bromide; vilanterol trifenatate. One supplier is listed for this compound.

Summary for umeclidinium bromide; vilanterol trifenatate

Pharmacology for umeclidinium bromide; vilanterol trifenatate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
GlaxosmithklineANORO ELLIPTAumeclidinium bromide; vilanterol trifenatatePOWDER;INHALATION203975-001Dec 18, 2013RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
GlaxosmithklineANORO ELLIPTAumeclidinium bromide; vilanterol trifenatatePOWDER;INHALATION203975-001Dec 18, 2013RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
GlaxosmithklineANORO ELLIPTAumeclidinium bromide; vilanterol trifenatatePOWDER;INHALATION203975-001Dec 18, 2013RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
GlaxosmithklineANORO ELLIPTAumeclidinium bromide; vilanterol trifenatatePOWDER;INHALATION203975-001Dec 18, 2013RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
GlaxosmithklineANORO ELLIPTAumeclidinium bromide; vilanterol trifenatatePOWDER;INHALATION203975-001Dec 18, 2013RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
GlaxosmithklineANORO ELLIPTAumeclidinium bromide; vilanterol trifenatatePOWDER;INHALATION203975-001Dec 18, 2013RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
GlaxosmithklineANORO ELLIPTAumeclidinium bromide; vilanterol trifenatatePOWDER;INHALATION203975-001Dec 18, 2013RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
GlaxosmithklineANORO ELLIPTAumeclidinium bromide; vilanterol trifenatatePOWDER;INHALATION203975-001Dec 18, 2013RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
GlaxosmithklineANORO ELLIPTAumeclidinium bromide; vilanterol trifenatatePOWDER;INHALATION203975-001Dec 18, 2013RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
GlaxosmithklineANORO ELLIPTAumeclidinium bromide; vilanterol trifenatatePOWDER;INHALATION203975-001Dec 18, 2013RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: umeclidinium bromide; vilanterol trifenatate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
GlaxosmithklineANORO ELLIPTAumeclidinium bromide; vilanterol trifenatatePOWDER;INHALATION203975-001Dec 18, 2013► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: umeclidinium bromide; vilanterol trifenatate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,982,067Phenethanolamine derivatives for treatment of respiratory diseases► Subscribe
8,575,347Muscarinic acetylcholine receptor antagonists► Subscribe
8,201,556Medicament dispenser► Subscribe
7,361,787Phenethanolamine derivatives for treatment of respiratory diseases► Subscribe
9,636,471Medicament dispenser► Subscribe
8,198,483Phenethanolamine derivatives for treatment of respiratory diseases► Subscribe
9,144,571Muscarinic acetylcholine receptor antagonists► Subscribe
9,045,469Muscarinic acetylcholine receptor antagonists► Subscribe
8,853,404Muscarinic acetylcholine receptor antagonists► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: umeclidinium bromide; vilanterol trifenatate

Country Document Number Estimated Expiration
Colombia5560552► Subscribe
Slovenia2570128► Subscribe
Norway20082701► Subscribe
Australia2003236835► Subscribe
United Kingdom0418278► Subscribe
Australia2014204459► Subscribe
Portugal2042168► Subscribe
European Patent Office1425001► Subscribe
Peru02592006► Subscribe
United Kingdom0217199► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90033-6Sweden► SubscribePRODUCT NAME: VILANTEROL, OCH SALTER OCH SOLVATER DAERAV; REG. NO/DATE: EU/1/13/886 20131113
1740177/02Switzerland► SubscribePRODUCT NAME: UMECLIDINIUM BROMID + VILANTEROL; REGISTRATION NO/DATE: SWISSMEDIC 63152 14.07.2014
C0075France► SubscribePRODUCT NAME: BROMURE D'UMECLIDINIUM; REGISTRATION NO/DATE: EU/1/14/922 001-003 20140428
90060-9Sweden► SubscribePRODUCT NAME: UMECLIDINIUM BROMIDE; REG. NO/DATE: EU/1/14/922 20140428
1425001/01Switzerland► SubscribePRODUCT NAME: VILANTEROL; REGISTRATION NO/DATE: SWISSMEDIC 62969 09.01.2014
2014019,C1425001Lithuania► SubscribePRODUCT NAME: VILANTEROLUM; REGISTRATION NO/DATE: EU/1/13/886/001-006 20131113
2014 00052Denmark► SubscribePRODUCT NAME: UMECLIDINIUMBROMID; REG. NO/DATE: EU/1/14/922/001-003 20140428
00694Netherlands► SubscribePRODUCT NAME: UMECLIDINIUMBROMIDE; REGISTRATION NO/DATE: EU/1/14/922/001-003 20140428
2014038Lithuania► SubscribePRODUCT NAME: UMECLIDINIUM BROMIDIUM; REGISTRATION NO/DATE: EU/1/14/922 20140428
2014038,C1740177Lithuania► SubscribePRODUCT NAME: UMEKLIDINO BROMIDAS; REGISTRATION NO/DATE: EU/1/14/922 20140428
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
Deloitte
Healthtrust
Chinese Patent Office
Chubb
Farmers Insurance
Julphar
Baxter
Citi
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot